The effect of the α2-agonist dexmedetomidine and the N-methyl-D-aspartate antagonist S(+)-ketamine on the expression of apoptosis-regulating proteins after incomplete cerebral ischemia and reperfusion in rats

Anesthesia and Analgesia

Volumn 96, Issue 2, 2003, Pages 524-531

  Engelhard, Kristin ^a   Werner, Christian ^a   Eberspächer, Eva ^a   Bachl, Monika ^a   Blobner, Manfred ^a   Hildt, Eberhard ^c   Hutzler, Peter ^b   Kochs, Eberhard ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b INSTITUTE OF EPIDEMIOLOGY   (Germany)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

APOPTOSIS REGULATING PROTEIN; DEXMEDETOMIDINE; FENTANYL; ISOFLURANE; KETAMINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NITROUS OXIDE; PROTEIN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN MDM2; PROTEIN P53; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLEEDING; BRAIN ISCHEMIA; BRAIN SLICE; CAROTID ARTERY OBSTRUCTION; CONTROLLED STUDY; HYPOTENSION; IMMUNOFLUORESCENCE; MALE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REPERFUSION; WESTERN BLOTTING;

ADRENERGIC ALPHA-AGONISTS; ANIMALS; APOPTOSIS; BLOOD GAS ANALYSIS; BLOTTING, WESTERN; BRAIN CHEMISTRY; BRAIN ISCHEMIA; CEREBROVASCULAR CIRCULATION; DEXMEDETOMIDINE; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION REGULATION; HEMODYNAMIC PROCESSES; KETAMINE; MALE; PROTEASE INHIBITORS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ADRENERGIC, ALPHA-2; RECEPTORS, N-METHYL-D-ASPARTATE; REPERFUSION INJURY;

EID: 0037302813     PISSN: 00032999     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000539-200302000-00041     Document Type: Article

References (26)

1. Reeker W, Werner C, Möllenberg O, et al. High-dose S(+)-ketamine improves neurological outcome following incomplete cerebral ischemia. Can J Anaesth 2000;47:572-8.
2. Hoffman WE, Baughman VL, Albrecht RF. Interaction of catecholamines and nitrous oxide ventilation during incomplete brain ischemia in rats. Anesth Analg 1993;77:908-12.
3. Hoffman WE, Kochs E, Werner C, et al. Dexmedetomidine improves neurologic outcome from incomplete ischemia in the rat. Anesthesiology 1991;75:328-32.
4. Zilkha-Falb R, Ziv I, Nardi N, et al. Monoamine-induced apoptotic neuronal cell death. Cell Mol Neurobiol 1997;17:101-18.
5. Slagsvold HH, Marvik OJ, Eidem G, et al. Detection of high molecular weight DNA fragments characteristic of early stage apoptosis in cerebellar granule cells exposed to glutamate. Exp Brain Res 2000;135:173-8.
6. Qin Z-H, Wang Y, Chase TN. Stimulation of N-methyl-D-aspartate receptors induces apoptosis in rat brain. Brain Res 1996;725:166-76.
7. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72:248-54.
8. Tsujimoto Y, Gorham J, Cossman J, et al. The t(14;18) chromosome translocations involved in B-cell neoplasms result from mistakes in VDJ joining. Science 1985;229:1390-3.
9. Oltavi ZN, Milliman CL, Korsmeyer SJ. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 1993;74:609-19.
10. Kluck RM, Bossy-Wetzel E, Green DR, Newmeyer DD. The release of cytochrome c from mitochondria: a primary site for Bcl-2 regulation of apoptosis. Science 1997;275:1132-6.
11. Yang J, Liu X, Bhalla K, et al. Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked. Science 1997;275:1129-32.
12. Susin SA, Zamzami N, Castedo M, et al. Bcl-2 inhibits the mitochondrial release of an apoptogenic protease. J Exp Med 1996;184:1331-41.
13. Xiang J, Chao DT, Korsmeyer SJ. Bax-induced cell death may not require interleukin 1β-converting enzyme-like protease. Proc Natl Acad Sci U S A 1996;93:14559-63.
14. Papadopoulos MC, Koumenis IL, Xu L, Giffard RG. Potentiation of murine astrocyte antioxidant defence by bcl-2: protection in part reflects elevated glutathione levels. Eur J Neurosci 1998;10: 1252-60.
15. Antonawich FJ, Federoff HJ, Davis JN. Bcl-2 transduction, using a herpes simplex virus amplicon, protects hippocampal neurons from transient global ischemia. Exp Neurol 1999;156:130-7.
16. 1 Bax interaction after transient global ischemia. J Cereb Blood Flow Metab 1998;18:882-6.
17. Gillardon F, Lenz C, Waschke KF, et al. Altered expression of Bcl-2, Bcl-x, Bax, and c-Fos colocalizes with DNA fragmentation and ischemic cell damage following cerebral artery occlusion in rats. Mol Brain Res 1996;40:254-60.
18. Miyashita T, Krajewski S, Krajewska M, et al. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene 1994;9:1799-805.
19. Selvakumaran M, Lin HK, Miyashita T, et al. Immediate early up-regulation of bax expression by p53 but not TGFb1: a paradigm for distinct apoptotic pathways. Oncogene 1994;9:1791-8.
20. Li Y, Chopp M, Powers C, Jiang N. Apoptosis and protein expression after focal cerebral ischemia in rat. Brain Res 1997; 765:301-12.
21. Napieralski JA, Raghupathi R, McIntosh TK. The tumor-suppressor gene, p53, is induced in injured brain regions following experimental traumatic brain injury. Mol Brain Res 1999; 71:78-86.
22. Hirata H, Cadet JL. p53-knockout mice are protected against the long-term effects of methamphetamine on dopaminergic terminals and cell bodies. J Neurochem 1997;69:780-90.
23. Lakkaraju A, Dubinsky JM, Low WC, Rahman Y-E. Neurons are protected from excitotoxic death by p53 antisense oligonucleotides delivered in anionic liposomes. J Biol Chem 2001;276: 32000-7.
24. Momand J, Zambetti GP, Olson DC, et al. The Mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 1992;69:1237-45.
25. Oliner JD, Pietenpol JA, Thiagalingam S, et al. Oncoprotein Mdm-2 conceals the activation domain of tumor suppressor p53. Nature 1993;362:857-60.
26. 2O. Anesthesiology 1988;69: 192-8.